The inflammation-based prognostic score termed Glasgow prognostic score (GPS), composed of serum elevation of C-reactive protein (CRP) and decrease in albumin concentration, is the most validated inflammatory risk score in cancer and predicts survival in heart failure with reduced ejection fraction, mortality in acute coronary syndrome patients, and outcomes in patients with heart failure with preserved ejection fraction [10,11]. Here, CRP is linked to acute coronary syndrome.